Vericel Corporation (VCEL) – What Are Researchers Thinking About This Stock?

Shares of Vericel Corporation (NASDAQ:VCEL) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $57.20.

Several equities research analysts have commented on the company. Weiss Ratings upgraded Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Truist Financial cut their target price on shares of Vericel from $58.00 to $52.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. TD Cowen boosted their target price on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research note on Thursday, July 30th. Finally, Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th.

Insiders Place Their Bets

In other Vericel news, insider Jonathan Siegal sold 4,500 shares of Vericel stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total value of $220,050.00. Following the completion of the transaction, the insider owned 1,078 shares of the company’s stock, valued at approximately $52,714.20. The trade was a 80.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Vericel

Hedge funds have recently modified their holdings of the company. Lisanti Capital Growth LLC purchased a new position in Vericel during the second quarter worth approximately $5,356,000. Man Group plc purchased a new stake in shares of Vericel in the second quarter valued at approximately $2,998,000. Bank of New York Mellon Corp purchased a new stake in shares of Vericel in the second quarter valued at approximately $12,366,000. Scholtz & Company LLC purchased a new stake in shares of Vericel in the second quarter valued at approximately $2,287,000. Finally, Madison Asset Management LLC acquired a new position in shares of Vericel during the 2nd quarter worth approximately $2,230,000.

Vericel Stock Up 1.2%

Shares of VCEL opened at $43.04 on Tuesday. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of 90.49 and a beta of 1.02. Vericel has a 52 week low of $28.95 and a 52 week high of $49.32. The stock’s 50-day moving average price is $40.72 and its 200-day moving average price is $38.59.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The company had revenue of $77.46 million during the quarter, compared to analysts’ expectations of $72.70 million. During the same period last year, the business earned ($0.01) earnings per share. Vericel’s quarterly revenue was up 22.5% on a year-over-year basis. As a group, equities analysts anticipate that Vericel will post 0.54 EPS for the current fiscal year.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.